<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Terman SW</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>University of Michigan</funding><funding>NIA NIH HHS</funding><funding>Epilepsy Society</funding><funding>NINDS NIH HHS</funding><funding>National Institutes of Health</funding><funding>National Institute on Aging</funding><pagination>107615</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12849773</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>217</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Antiseizure medications (ASMs) represent standard treatment for epilepsy. Yet, ASMs have adverse effects, and seizure risk decreases with longer seizure freedom. Guidelines consider ASM withdrawal after a period of seizure freedom. However, work exploring how patients approach this decision is scarce. We inquired what decision-making factors patients feel are relevant to ASM discontinuation.&lt;h4>Methods&lt;/h4>We conducted a mixed-methods study of adults seen for epilepsy, at least one-year seizure-free, across three academic institutions. This included a semi-structured interview script assessing attitudes towards seizures, ASMs, and ASM discontinuation.&lt;h4>Results&lt;/h4>We interviewed 32 participants. Factors supporting ASM discontinuation included current side effects (e.g.</pubmed_abstract><journal>Epilepsy research</journal><pubmed_title>Antiseizure medication discontinuation: A mixed-methods exploration of factors considered by patients when approaching decision-making.</pubmed_title><pmcid>PMC12849773</pmcid><funding_grant_id>K23 AG081463</funding_grant_id><funding_grant_id>K23 NS126495</funding_grant_id><funding_grant_id>K23NS126495</funding_grant_id><pubmed_authors>Kalia N</pubmed_authors><pubmed_authors>Mortati K</pubmed_authors><pubmed_authors>Manuel K</pubmed_authors><pubmed_authors>Burke JF</pubmed_authors><pubmed_authors>Silva JM</pubmed_authors><pubmed_authors>Kuster M</pubmed_authors><pubmed_authors>Grant AC</pubmed_authors><pubmed_authors>Brand A</pubmed_authors><pubmed_authors>Lee J</pubmed_authors><pubmed_authors>Tolmasov A</pubmed_authors><pubmed_authors>O'Kula SS</pubmed_authors><pubmed_authors>Terman SW</pubmed_authors><pubmed_authors>Hill CE</pubmed_authors><pubmed_authors>Patel PS</pubmed_authors><pubmed_authors>Reid M</pubmed_authors><pubmed_authors>Dugan M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antiseizure medication discontinuation: A mixed-methods exploration of factors considered by patients when approaching decision-making.</name><description>&lt;h4>Objectives&lt;/h4>Antiseizure medications (ASMs) represent standard treatment for epilepsy. Yet, ASMs have adverse effects, and seizure risk decreases with longer seizure freedom. Guidelines consider ASM withdrawal after a period of seizure freedom. However, work exploring how patients approach this decision is scarce. We inquired what decision-making factors patients feel are relevant to ASM discontinuation.&lt;h4>Methods&lt;/h4>We conducted a mixed-methods study of adults seen for epilepsy, at least one-year seizure-free, across three academic institutions. This included a semi-structured interview script assessing attitudes towards seizures, ASMs, and ASM discontinuation.&lt;h4>Results&lt;/h4>We interviewed 32 participants. Factors supporting ASM discontinuation included current side effects (e.g.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-16T07:18:34.265Z</modification><creation>2026-06-16T03:09:39.401Z</creation></dates><accession>S-EPMC12849773</accession><cross_references><pubmed>40540761</pubmed><doi>10.1016/j.eplepsyres.2025.107615</doi></cross_references></HashMap>